SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff Deadline

STEVENSON, Md., Feb. 12, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers” or the “Company”) securities during the period between January 27, 2015 and October 9, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 10, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Bristol-Myers securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Bristol-Myers’ CheckMate-026 trial was more likely to fail than Defendants were representing and that Bristol-Myers’ CheckMate-026 trial failed more severely than the Company indicated in the Company’s August 5, 2016 announcements.

According to the complaint, following an August 5, 2016 announcement that CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed for not meeting its primary endpoint of progression-free survival, and an October 9, 2016 announcement that the final primary analysis of CheckMate-026 and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months, the value of Bristol-Myers shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Bristol-Myers securities purchased on or after January 27, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]